4basebio Company Description

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally.

The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccines and therapeutics; and oeDNA, or open ended DNA, a linear, double stranded DNA product ideal for genome editing.

It also provides osDNA, or open stabilized DNA, a product incorporating nucleotide modifications within the DNA backbone enables tuning of the immunostimulatory properties of the construct for DNA vaccine applications; and The Hermes, a proprietary delivery platform for nucleic acid and protein payloads appears to offer a thermo-stable alternative to traditional lipid based delivery systems.

The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021.

4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.

4basebio PLC

Country	United Kingdom
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	110
CEO	Heikki Lanckriet

Contact Details

Address: 25 Norman Way Cambridge, CB24 5QE United Kingdom
Phone	44 1223 967 943
Website	4basebio.com

Stock Details

Ticker Symbol	4BB
Exchange	London Stock Exchange AIM
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00BMCLYF79
SIC Code	2836

Key Executives

Name	Position
Heikki Lanckriet	Chief Executive Officer
David Roth	Chief Financial Officer
Amy Walker	Chief Operating Officer